Diffusion-weighted MRI with ADC mapping for response prediction and assessment of oesophageal cancer: A systematic review

Oesophageal cancer is a malignancy with a poor prognosis, as reflected by an average overall 5-year survival of only 18% [1]. Locally advanced oesophageal cancer patients are generally treated by chemo- and/or radiotherapy, either as definite treatment or as neoadjuvant treatment prior to surgery [2 –4]. However, not all patients benefit equally. In 23% of adenocarcinomas (AC) and 49% of squamous cell carcinomas (SCC) a pathological complete response (pCR, tumour regression grade (TRG) 1) is determined on histopathology of the resection specimen after neoadjuvant chemoradiotherapy (nCRT) [2,5 ].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Systematic Review Source Type: research

Related Links:

Conclusions: Neoadjuvant radiation dose impacts pathological response in terms of pMR in oesophageal cancer patients. No radiation dose-response effect was observed for pCR. Further prospective trials are needed to investigate the dose-response relation in terms of pCR. PMID: 31432736 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Esophageal cancer is a highly lethal disease, especially in developing countries. China has been a high-incidence area of esophageal cancer for many years and accounts for over 50% of the global morbidity and mortality [1]. The two major histological types of esophageal cancer are squamous cell carcinoma (ESCC) and adenocarcinoma, and there is a striking geographical variation in the incidence of the esophageal cancer subtypes. In China, approximately 90% of patients with esophageal cancer are diagnosed with ESCC [2].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Esophageal cancer incidence in the Western world has risen over the past decades, with adenocarcinomas now being more prevalent than squamous cell carcinomas [1]. Alcohol intake, tobacco smoking and overweight are key risk factors, especially for adenocarcinomas. The disease is rarely curable with a 5-year overall survival of approximately 20% [2,3]. Standard treatment consists of neoadjuvant chemoradiotherapy followed by surgery [4].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Authors: Kelly RJ Abstract Esophageal cancer has a poor prognosis, with 5-year survival rates ranging from 20% to 35% in the nonmetastatic setting. Despite advances in surgical techniques and optimization of chemoradiotherapy regimens, overall survival benefits have been incremental at best. Esophageal cancer requires a concerted multidisciplinary approach, perhaps more so than any other tumor type given the integral role played by the esophagus in maintaining calorific intake and the propensity for early spread through the lymphatics. This review describes the latest in surgical techniques to minimize postoperativ...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Background: Neoadjuvant chemoradiation (CRT) remains controversial in the treatment of the oesophagus or gastro-oesophageal junction (GOJ) carcinomas.Methods: We conducted a meta-analysis to assess the efficacy and safety of Neoadjuvant CRT plus surgery comparing with neoadjuvant CT plus surgery or surgery alone. Feasible studies were searched from electronic databases. The outcomes of survival, R0 resection rate and adverse effects were analyzed. The outcomes were measured with relative risk (RR) and odds ratio(OR).Results: Seventeen records including 4095 patients were included. Neoadjuvant CRT improved 1-,2-,3-and 5-yea...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Abstract Human evolutionary genetic divergence and distinctive environmental exposures have contributed to the development of clinicopathologic variations of esophageal cancer in Eastern and Western countries. Different treatment strategies have derived from the disparate regional experiences. Treatment strategy is more standardized in the West. Trimodality treatment with neoadjuvant chemoradiation followed by surgery is widely accepted as the standard treatment of locally advanced esophageal adenocarcinoma and esophageal squamous cell carcinoma. Trimodality treatment has not been adopted in many Eastern countries...
Source: The Surgical Clinics of North America - Category: Surgery Authors: Tags: Surg Clin North Am Source Type: research
Conclusions: In OSCC, very low preoperative NLR values have a negative prognostic impact on survival and recurrence, similarly to high ratios. ENE and perineural spread are the most important clinical-pathologic prognosticators. Introduction Oral squamous cell carcinoma (OSCC) accounts for more than 95% of oral tumors and is the eighth most frequent cancer worldwide, with an estimated incidence of 640,000 new cases per year (1). Survival of OSCC has slightly improved over the last 30 years, probably as a consequence of multimodal treatment spreading. However, intensified therapeutic regimens can result in signific...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study aimed to investigate whether combining anti-PD-L1 Atezolizumab with BEV may have a synergistic effect and enhance the efficacy of both treatments in cisplatin resistant epithelial ovarian cancer (CREOC). We retrospectively analyzed 124 epithelial ovarian cancer (EOC) patients from Gynecologic Oncology Department of Tianjin Cancer Hospital between January 2013 and June 2018, who all were diagnosed with cisplatin resistance due to progressing
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Joe Abdo1, Christopher S. Wichman2, Nicholas E. Dietz1,3, Pawel Ciborowski4, John Fleegel1, Sumeet K. Mittal1,5 and Devendra K. Agrawal1* 1Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, NE, United States 2Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States 3Department of Pathology, CHI Health Creighton University Medical Center, College of Medicine, Omaha, NE, United States 4Department of Pharmacology, University of Nebraska Medical Center, Omaha, NE, United States 5Norton Thoracic Institute, St....
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study will contribute more evidence to the management of oesophageal squamous cell cancer.Trial registrationClinicalTrials.gov,NCT02972372. Registered on 26 November 2016.
Source: Trials - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Esophagus Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Radiology | Squamous Cell Carcinoma